AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

Technology for Enhanced Vaccine Development

Technology Benefits

Identification of novel peptides that will initiate robust protective immune responses to microorganisms and parasites like tuberculosis, listeria, malaria, and many othersUses the cells own machinery to generate the antigenic MHC II restricted peptides

Technology Application

vaccine development

Detailed Technology Description

Very little is known about the experimental or therapeutic regulation of antigenic peptide occupancy of major histocompatibility (MHC) molecules, particularly in the case of the MHC class II molecules. The opportunity to regulate MHC antigenic peptide occupancy with small molecules could greatly increase our ability to identify peptides that can occupy the MHC binding clefts and thereby interact efficiently with T-cells for initiating effective, robust immune responses.To this end, USF Researchers have developed a novel process that utilizes histone deacetylase inhibitors (HDACIΓÇÖs). Data demonstrate that HDACIΓÇÖs can regulate HLA-DR peptide occupancy. The treatment with HDACIΓÇÖs alters the peptidome of cells by regulating components of the MHC II class antigen processing machinery.This technology can be utilized to identify novel immunogenic MHCII peptides that can be used for general or personalized vaccination strategies involving pathogen or tumor proteins.

Country/Region

USA

For more information, please click Here